March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • HHS Issues Alert on Info Blocking Enforcement

    HHS issued an enforcement alert that info blocking rules still apply. ACR has radiology-focused guidance and FAQs available.

    Read more
  • MedPAC Meeting Highlights Medicare Policy

    The MedPAC meeting included discussions about improving payment accuracy and the Medicare program’s overall financial situation.

    Read more
  • Report Backs NIH Changes to Reduce Childhood Chronic Diseases

    The report includes a recommendation that NIH launch a chronic disease initiative using a whole-person approach to research chronic disease prevention.

    Read more